Stronger Euro Could Make Bayer’s Full-Year Sales Target “Ambitious”
This article was originally published in The Pink Sheet Daily
The German conglomerate highlights sales of its five new medicines that have gotten off to good starts in the marketplace and has identified another five early stage cardiology and oncology products to push through its pipeline.
You may also be interested in...
Bayer saw 40% of its revenues come from emerging markets in the fourth quarter of 2013. The health care business unit lagged in Asia for the year, but the company expects rapid growth in China through acquisitions and other expansion plans.
Newer drugs at Bayer helped the bottom line in the third quarter while the world’s top insulin maker Novo Nordisk missed expectations, but held out emerging markets as a bright spot. Teva tussled with analysts on the surprise exit of Jeremy Levin and said that many of the plans during his brief tenure were driven by the board and remain in place.
Diabetic nephropathy, pancreatic islet cell health as well as heart failure will feature in early-stage research conducted by AstraZeneca's cardiometabolic iMED based in Mölndal, Sweden - now one of three strategic R&D centers for the trimmed-down British drug maker.